Allogene Therapeutics Inc’s recently made public that its Director MESSEMER DEBORAH M. unloaded Company’s shares for reported $42488.0 on Jun 18 ’24. In the deal valued at $2.28 per share,18,641 shares were sold. As a result of this transaction, MESSEMER DEBORAH M. now holds 166,765 shares worth roughly $0.39 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Humer Franz B sold 11,200 shares, generating $26,181 in total proceeds. Upon selling the shares at $2.34, the Director now owns 255,253 shares.
Before that, Belldegrun Arie bought 1,724,137 shares. Allogene Therapeutics Inc shares valued at $4,999,997 were divested by the Director at a price of $2.90 per share. As a result of the transaction, Belldegrun Arie now holds 1,724,137 shares, worth roughly $4.02 million.
Piper Sandler initiated its Allogene Therapeutics Inc [ALLO] rating to an Overweight in a research note published on May 31, 2024; the price target was $11. A number of analysts have revised their coverage, including JMP Securities’s analysts, who decreased its forecast for the stock in early January from “a Mkt outperform” to “a Mkt perform”. Guggenheim also remained covering ALLO and has decreased its forecast on January 05, 2024 with a “Neutral” recommendation from previously “Buy” rating. Citigroup started covering the stock on December 08, 2023. It rated ALLO as “a Buy”.
Price Performance Review of ALLO
On Friday, Allogene Therapeutics Inc [NASDAQ:ALLO] saw its stock fall -4.51% to $2.33. Over the last five days, the stock has lost -8.63%. Allogene Therapeutics Inc shares have fallen nearly -27.41% since the year began. Nevertheless, the stocks have fallen -49.68% over the past one year. While a 52-week high of $6.05 was reached on 03/08/24, a 52-week low of $2.18 was recorded on 06/18/24. SMA at 50 days reached $2.70, while 200 days put it at $3.33. A total of 3.58 million shares were traded, compared to the trading of 2.37 million shares in the previous session.
Levels Of Support And Resistance For ALLO Stock
The 24-hour chart illustrates a support level at 2.25, which if violated will result in even more drops to 2.17. On the upside, there is a resistance level at 2.43. A further resistance level may holdings at 2.52. The Relative Strength Index (RSI) on the 14-day chart is 42.51, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.07, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 70.01%. Stochastics%K at 37.99% indicates the stock is a holding.
The most recent change occurred on December 08, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating.
